GIP does not potentiate the antidiabetic effects of GLP-1 in hyperglycemic patients with type 2 diabetes - Wikidata - wikimedia - TriplyDB

GIP does not potentiate the antidiabetic effects of GLP-1 in hyperglycemic patients with type 2 diabetes

GIP does not potentiate the antidiabetic effects of GLP-1 in hyperglycemic patients with type 2 diabetes

http://www.wikidata.org/entity/Q34718860

about

Pancreatic regulation of glucose homeostasis Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond GLP-1, the gut-brain, and brain-periphery axes Clinical utility in the treatment of type 2 diabetes with the saxagliptin/metformin fixed combination Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease Gut-brain connection: The neuroprotective effects of the anti-diabetic drug liraglutide Alogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus.GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other?Effects of glucose-dependent insulinotropic polypeptide on gastric emptying, glycaemia and insulinaemia during critical illness: a prospective, double blind, randomised, crossover study.The role of endogenous incretin secretion as amplifier of glucose-stimulated insulin secretion in healthy subjects and patients with type 2 diabetes.Resistin regulates pituitary lipid metabolism and inflammation in vivo and in vitro.Short-term administration of the GLP-1 analog liraglutide decreases circulating leptin and increases GIP levels and these changes are associated with alterations in CNS responses to food cues: A randomized, placebo-controlled, crossover study.Mechanisms of glucose lowering of dipeptidyl peptidase-4 inhibitor sitagliptin when used alone or with metformin in type 2 diabetes: a double-tracer study.The effect of exogenous glucose-dependent insulinotropic polypeptide in combination with glucagon-like peptide-1 on glycemia in the critically ill.The dipeptidyl peptidase (DPP)-4 inhibitors for type 2 diabetes mellitus in challenging patient groups.Choosing a gliptin.Dysglycaemia in the critically ill - significance and management.An overview of new GLP-1 receptor agonists for type 2 diabetes.Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes.Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.Inter-regulation of gastric emptying and incretin hormone secretion: implications for postprandial glycemic control.Ghrelin, CCK, GLP-1, and PYY(3-36): Secretory Controls and Physiological Roles in Eating and Glycemia in Health, Obesity, and After RYGB.Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans.Menin and GIP are inversely regulated by food intake and diet via PI3/AKT signaling in the proximal duodenum.A novel GIP analogue, ZP4165, enhances glucagon-like peptide-1-induced body weight loss and improves glycaemic control in rodents.The incretin hormones: from scientific discovery to practical therapeutics.

P2860

Q26766485-3C297AA7-C290-4318-90BA-B17623D7BE86 Q26778608-47ABAEAB-8B46-4A9C-8312-7DD56D14F575 Q26799389-39DB38DA-5578-4C31-9CF4-DA0698095F04 Q27000749-7D739843-73ED-4789-AA49-F6592C84F33F Q27026211-7584E776-AB7D-4364-8B32-2EF1FE0C202E Q27027920-E3C61D59-C8A1-44E7-BE18-90152A486E22 Q28081671-F0EA9536-971F-4418-ABF5-87D6D38042E2 Q33874654-BC2B3D7E-2B20-4244-B43E-9353ECFF0DCD Q34547492-6EE43D22-5232-4411-A599-1AE28F74AB76 Q35122108-9A8F39A0-B318-4CDA-A728-B9227B2EB426 Q36182540-BDA5A349-0F69-4532-B605-F358409FDA57 Q36844999-BFD5E2FC-E848-475B-9998-E3FBD731E27E Q36994382-F092E99A-4410-43CD-951A-895186CFDC8A Q37106470-87C6A48F-058A-4422-AA87-ECBA83ADCBBA Q37193583-93A00374-FC09-4790-9B72-A0186F90B2FE Q37502682-826DA2CF-AB05-4CB6-971B-C93B81472736 Q37949599-F88E5152-EF50-4F94-841D-1A8FBA287F75 Q38078016-F040C1A6-B711-43A0-87B5-B35494D4266E Q38639922-52714942-173B-4375-9CD9-4B46F8866BEC Q38690867-12196684-0EA0-4EFB-B16E-CB3962144BBD Q38830154-AF4BCFF0-9EA2-417E-A762-807B81CCDAC3 Q38979407-938BC7DE-3095-4519-B9D0-377493AC2600 Q39047697-B5D31175-2956-42F8-9342-632A67C9E480 Q39221120-AA2F7226-B46A-42DB-B2DC-D67C15877F34 Q42117088-2830AAC0-2A67-48D7-AFE9-7EB718F5859F Q47207365-9DB79BCF-08FC-4918-B587-99732C3A1109 Q51357360-B0DEDD02-D798-4885-904F-5ACA01238DE1

P2860

GIP does not potentiate the antidiabetic effects of GLP-1 in hyperglycemic patients with type 2 diabetes

http://www.wikidata.org/entity/Q34718860

description

2011 nî lūn-bûn

@nan

2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

GIP does not potentiate the an ...... patients with type 2 diabetes

@ast

GIP does not potentiate the an ...... patients with type 2 diabetes

@en

GIP does not potentiate the an ...... patients with type 2 diabetes

@nl

type

label

GIP does not potentiate the an ...... patients with type 2 diabetes

@ast

GIP does not potentiate the an ...... patients with type 2 diabetes

@en

GIP does not potentiate the an ...... patients with type 2 diabetes

@nl

prefLabel

GIP does not potentiate the an ...... patients with type 2 diabetes

@ast

GIP does not potentiate the an ...... patients with type 2 diabetes

@en

GIP does not potentiate the an ...... patients with type 2 diabetes

@nl

P1433

Q34718860-9DDBC180-8D8E-437C-A42F-CF30D585EC91

P1476

Q34718860-F45FC1C9-FD39-4673-A668-1E2F90C3AF34

P2093

Q34718860-1DF4FDD6-90AA-41F1-BB54-48DC4748CEC8

Q34718860-48448979-050C-4C62-BDB7-97B0781AB493

Q34718860-62DEC621-351B-48EB-9B48-1D3939FB4C29

Q34718860-9E068294-538C-467D-8911-ABB0B1D1307C

Q34718860-A70C69A7-10D3-44FB-A060-DF5B13A898FE

Q34718860-AAB323C7-F671-47DD-AED4-CEF403F7FBF9

P2860

Q34718860-0A930AE8-CD81-4EFF-84EE-C92538355FF5

Q34718860-0CBAEA18-AC18-42C2-AEC7-F933FF6C65D7

Q34718860-0FF07A14-315D-4710-AA26-8ADAB6CF6F02

Q34718860-165F7B9E-64C3-45B8-A262-FDAE20A33352

Q34718860-1867C882-1564-487F-A937-7C478691D992

Q34718860-1A8673B4-2CF8-4038-A090-9BCA19F31758

Q34718860-1D051CA5-BCDB-4789-A6DC-A166F92ED7D9

Q34718860-26A9CEEF-9ECB-46A8-BC85-E1EE7B2FE235

Q34718860-27F5A74F-D6EA-49E2-802C-5E7DC55A63C7

Q34718860-3133ADA6-0C78-4BCA-BA13-C57DD0FC3CBC

P304

Q34718860-1689B3DC-E381-497B-9A62-85B2E3336DD3

P31

Q34718860-A1939C6D-4D4E-4224-A00F-F350274C8F22

P356

Q34718860-6799F49F-7104-4AA8-829D-1E54473758A9

P407

Q34718860-8D19AE56-6035-4C9E-81AC-B0F4388A7345

P433

Q34718860-BA10D15C-431C-43EB-B95B-BA411D605903

P478

Q34718860-1477D632-2553-4AE2-B24C-B10EC263FD74

P50

Q34718860-3D10C8C9-2568-4445-B763-445CF870258D

Q34718860-E6609E97-6D86-4E0C-AC26-724D2870F3B4

P577

Q34718860-D577457E-A11C-4C5E-805F-B14F5A9ACA3A

P5875

Q34718860-5F51B5F1-6D81-42D2-9AC0-B63F47CBB364

P698

Q34718860-FAB73231-72A6-42B2-A825-89C5EAF06972

P921

Q34718860-10A143AE-2578-4B8A-A826-BE57FA2770D7

Q34718860-143E3305-14A4-4248-8C5C-09DDBA98048F

Q34718860-3C4791B6-7ACC-4A1E-B708-3302650F7317

P932

Q34718860-58CBF871-0180-46DB-8743-F6942D9EEB0B

P356

P1433

P1476

GIP does not potentiate the an ...... patients with type 2 diabetes

@en

P2093

Irfan Vardarli

http://www.w3.org/2001/XMLSchema#string

Juris J Meier

http://www.w3.org/2001/XMLSchema#string

Lars D Köthe

http://www.w3.org/2001/XMLSchema#string

Michael A Nauck

http://www.w3.org/2001/XMLSchema#string

Michael Theodorakis

http://www.w3.org/2001/XMLSchema#string

Nikolaos Mentis

http://www.w3.org/2001/XMLSchema#string

P2860

Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans.

Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

DPP IV resistance and insulin releasing activity of a novel di-substituted analogue of glucose-dependent insulinotropic polypeptide, (Ser2-Asp13)GIP.

Antidiabetic potential of two novel fatty acid derivatised, N-terminally modified analogues of glucose-dependent insulinotropic polypeptide (GIP): N-AcGIP(LysPAL16) and N-AcGIP(LysPAL37).

GIP(Lys16PAL) and GIP(Lys37PAL): novel long-acting acylated analogues of glucose-dependent insulinotropic polypeptide with improved antidiabetic potential.

Use of biosynthetic human C-peptide in the measurement of insulin secretion rates in normal volunteers and type I diabetic patients.

Glucose-dependent insulinotropic polypeptide analogues and their therapeutic potential for the treatment of obesity-diabetes.

Glucose-dependent insulinotropic polypeptide (GIP): anti-diabetic and anti-obesity potential?

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

P304

1270-1276

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DB10-1332

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

60

http://www.w3.org/2001/XMLSchema#string

P50

Jens Juul Holst

Carolyn F. Deacon

P577

2011-02-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49845024

http://www.w3.org/2001/XMLSchema#string

P698

21330636

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

3064100

http://www.w3.org/2001/XMLSchema#string